Browsing Tag
Celltrion
6 posts
Can Celltrion’s Eydenzelt disrupt Canada’s aflibercept market after Health Canada approval?
Celltrion secures Health Canada approval for Eydenzelt, its aflibercept biosimilar. Explore how it aims to disrupt Canada’s high-cost eye care drug market.
Celltrion’s Eydenzelt gets FDA nod — Is Eylea finally facing a real biosimilar rival?
Find out how Celltrion’s FDA-approved Eydenzelt is set to challenge Eylea and reshape the biosimilar landscape for retinal diseases in 2025.
Celltrion’s YUFLYMA gains full FDA interchangeability: What it means for U.S. biosimilar market
Discover how Celltrion’s YUFLYMA earned full FDA interchangeability, boosting biosimilar adoption and reshaping the U.S. immunology drug market.
Celltrion gains EC approval for Avtozma, a RoActemra biosimilar for autoimmune diseases
Celltrion has received marketing authorization from the European Commission (EC) for Avtozma, a biosimilar to RoActemra (tocilizumab), expanding…
Three biosimilars by Celltrion near EU approval following CHMP endorsement
Celltrion, a leading South Korean biopharmaceutical company, has received positive opinions from the European Medicines Agency’s (EMA) Committee…
Hasten Biopharmaceutical buys asset rights for 14 branded products from Celltrion
In a significant move, CBC Group, Asia’s largest healthcare-dedicated asset management firm headquartered in Singapore, announced that its…